Aduhelm

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm

Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes

Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm

Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes

Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst

Biogen - Eisai Launch 5-Year Study To See How Well Alzheimer's Drug Aduhelm Works In Real World

Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst

Biogen - Eisai Launch 5-Year Study To See How Well Alzheimer's Drug Aduhelm Works In Real World

After Aduhelm Win, Biogen Touts Encouraging Data From Second Alzheimer's Candidate

Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients

Aduhelm Recent News

FDA Requests Probe Into Staff Interactions With Biogen Ahead Of Aduhelm Approval

FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients

Biogen Inc. (NASDAQ: BIIB) shares are lower after the company announced an updated label for its recently-approved Alzheimer's treatment Adu

Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug

With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch

Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm.